Clinical Trial Update: Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating motexafin gadolinium in combination with pemetrexed for second-line non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Motexafin Gadolinium (motexafin gadolinium)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Non-Small Cell Lung Carcinoma | Phase 2 | Status: TERMINATED